Facebook Twitter Linkedin NASDAQ Market NewsClick here to email authorNEXT STORYPM360 Announces the Selections for its 8th Annual Innovations IssuePREV STORYInnovation Pharmaceuticals Granted Regulatory Approval to Start Phase 1 Trial of Oral Brilacidin in Ulcerative Colitis Program; Company Aims to Capture Large Market Opportunity for Novel Oral IBD Drug Candidates